FDA Clearance to Proceed with Ph 1b/2 Trial of ADG126 SAFEbody® in Combination with Pembrolizumab Announced March 17, 2022
FDA Clears IND for Phase 1b/2 Trial of ADG116 in Combination with Pembrolizumab in Patients with Solid Tumors November 30, 2021